Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketamine intranasal - Seelos Therapeutics

Next Previous
Drug Profile

Ketamine intranasal - Seelos Therapeutics

Alternative Names: Ereska; IN Ketamine; Intranasal ketamine; Intranasal racemic ketamine; PMI-100; PMI-150; SLS-002; TUR-002

Latest Information Update: 28 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Javelin Pharmaceuticals
  • Developer Seelos Therapeutics; US Army Medical Research and Development Command
  • Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
  • Mechanism of Action AMPA receptor agonists; Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Post-traumatic stress disorders; Suicidal ideation
  • Discontinued Acute pain; Cancer pain

Most Recent Events

  • 28 Mar 2026 No recent reports of development identified for phase-I development in Suicidal-ideation(In volunteers) in Japan (Intranasal)
  • 13 Feb 2025 Global Coalition for Adaptive Research plans a phase II trial for Post-traumatic stress disorders (Intranasal) in the USA in June 2025 (NCT06816433)
  • 24 Sep 2024 Seelos Therapeutics signs Material Transfer Agreement United States Army Medical Research and Materiel Command to evaluate its potential for treatment of post-traumatic stress disorder

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top